Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageIB-IIIA non-small cell lung cancer.

8508Background: Adjuvant or neoadjuvant chemotherapy increased 5% survival compared with surgery alone for completely resected stage II-IIIa NSCLC. No significant difference in overall survival among adjuvant vs neoadjuvant vs surgery was found in NATCH study. Clinical issue is how to select adjuvant or neoadjuvant therapy for resectable NSCLC. Methods: Patients with stage IB-IIIA NSCLC were eligible. Adjuvant or neoadjuvant chemo regimen was designed as 3 cycles DC (Docetaxel: 75mg/m2, Carboplatin:AUC = 5 on day 1 every 3wks). The primary end point was 3yrs disease Free Survival (DFS) rate; secondary end points were 3yrs and 5yrs Overall Survival (OS) and Safety. The trial was closed early due to stage IB was not eligible since 2008 and slow accrual. The preliminary results were reported at 2013 ASCO & 2016 ESMO. Results: 214 patients were screened from 13 sites from March 2006 to …